HeartSciences Inc. (HSCSW) Aandelenanalyse

Bedrijfsoverzicht

HeartSciences Inc. is a medical technology enterprise dedicated to enhancing clinical utility through the application of artificial intelligence to electrocardiogram (ECG) data, specifically developing AI-enhanced solutions designed to detect impaired cardiac relaxation or dysfunction. Although specific sector and industry classifications are not publicly disclosed in the available data, the company operates within the specialized medical device and software domain, focusing on algorithmic analysis of cardiac signals. The organization maintains a lean operational footprint with a workforce of 15 employees, generating a trailing twelve-month revenue of $8,669. These financial figures, coupled with the absence of a reported market capitalization, indicate that the company is in an early-stage development phase where revenue generation is limited and capital markets have not yet assigned a standard valuation multiple.

Financiële gezondheid

The company reported a trailing twelve-month revenue of $8,669 against a net income loss of $8,485,301 and an EBITDA loss of $7,768,315. The substantial disparity between the minimal revenue and the significant net income deficit reveals a cost structure dominated by high operating expenses, likely driven by research and development costs and administrative overheads that far exceed current sales. Free cash flow stands at a negative $4,213,324, which signifies that the company is burning cash to fund its operations and product development, thereby limiting its financial flexibility to pursue organic growth without external financing. Margin analysis shows a gross margin of 57.9%, suggesting that the cost of goods sold for its ECG solutions is relatively low compared to sales, yet the operating margin of -89,939.6% and profit margin of 0.0% demonstrate severe inefficiencies where operating expenses are disproportionately high relative to revenue. On the balance sheet, total cash reserves of $3.40M are insufficient to cover total debt obligations of $3.87M, resulting in a debt-to-equity ratio of 145.81% that indicates a highly leveraged financial position. The current ratio of 1.19 suggests that for every dollar of current liabilities, the company holds $1.19 in current assets, providing a minimal buffer for short-term liquidity needs. Return on equity is negative at -382.3% and return on assets is negative at -73.5%, metrics that reveal that management has not yet been effective in generating profitable returns on the capital invested in the business.

Waarderingsbeoordeling

Trailing P/E and forward P/E ratios are not applicable (N/A) due to the company's lack of positive earnings, which implies that traditional earnings-based valuation models cannot be applied to assess the current trajectory of profitability. The price-to-book ratio is 0.14, indicating that the market values the company at significantly less than its book value, reflecting investor skepticism regarding the realization of its intangible assets and future potential. Since price-to-sales and EV/EBITDA metrics are unavailable (N/A), alternative valuation perspectives rely heavily on the price-to-book multiple and cash position to gauge worth. The stock's 52-week high and low are both recorded at $0.12, meaning the share price is currently trading within a flat range with no deviation from the recent trading floor. A beta of 2.45 indicates that the stock's price volatility is more than twice that of the broader market, exposing holders to significant fluctuations driven by sentiment in the small-cap and biotech sectors.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are not applicable (N/A), preventing a direct comparison of whether earnings are expanding faster or slower than sales. As the company does not pay a dividend, with a dividend yield and payout ratio listed as N/A, it does not distribute income to shareholders. Consequently, the company must reinvest all available cash flow, or seek additional capital, into research, development, and operational scaling rather than returning value via dividends. The overall growth and income profile is characterized by a lack of historical growth data, a complete absence of dividend income, and a reliance on external capital markets to fund operations given the negative free cash flow and negative earnings.